Newbury Pharmaceuticals Q1 Report: Ramp-up in sales

Research Update

2024-01-11

07:30

Redeye provides a research update following the Q1 report published by Newbury yesterday. We make some upward adjustments to our estimates for future sales growth following stronger sales figures than anticipated. Accordingly, we raise our fair value base case valuation to SEK9 (8.5).

Kevin Sule

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.